Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Tomás Pascual, Daniel G. Stover, Astrid Thuerigen, Rodrigo Sanchez-Bayona, Charles M. Perou, Eva M Ciruelos, Ana Casas, Patricia Spears, Estelle Roux, Fei Su, Huilin Hu, Yen-Shen Lu, Sara M. Tolaney, Ann H. Partridge, Guillermo Villacampa, Juan Manuel Ferrero-Cafiero, Lisa A. Carey, Aleix Prat
Institutions: Hospital Clínic de Barcelona, Solti, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Novartis (United States), Hospital Universitario 12 De Octubre, University of North Carolina at Chapel Hill, Novartis (Switzerland), National Taiwan University Hospital, Dana-Farber Cancer Institute, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379284535